PetMed Express adds Tamar Elkeles to board
PetMed Express adds independent director Tamar Elkeles and expands its Board to five members, emphasizing governance, compensation and human capital oversight.
Rhea-AI Filing Summary
PetMed Express, Inc. (PETS) announced that its Board of Directors appointed Tamar Elkeles, Ph.D. as an independent director effective September 17, 2026, and increased the Board size to 5 directors.
She will serve until the 2027 annual meeting or until a successor is elected and qualified. The Board determined she is an independent director under Nasdaq listing standards and the Company’s Corporate Governance Guidelines. Dr. Elkeles will serve as Chair of the Compensation and Human Capital Committee and as a member of the Corporate Governance and Nominating Committee, receiving compensation under the existing Non-Employee Director Compensation Program and an indemnification agreement consistent with other directors. The company also issued a press release on September 21, 2026 describing her appointment and background.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Board size after appointment: 5 directors
Director term: Until 2027 annual meeting
Effective date of appointment: September 17, 2026
+5 more
8 metrics
Board size after appointment
5 directors
Number of PetMed Express Board members after adding Tamar Elkeles
Director term
Until 2027 annual meeting
Tamar Elkeles will serve as director until the 2027 annual shareholders’ meeting or until a successor is elected and qualified
Effective date of appointment
September 17, 2026
Date Tamar Elkeles’ service as a director became effective
Director age
57
Age of Tamar Elkeles at the time of appointment
Professional experience
Over 30 years
Years of experience of Tamar Elkeles as executive, board member, and strategic advisor
Qualcomm revenue range cited
$100 million to more than $25 billion
Growth range referenced for Qualcomm during Tamar Elkeles’ tenure as Chief Learning & Talent Officer
Qualcomm workforce growth cited
700 to 35,000 employees
Global workforce range referenced for Qualcomm during Tamar Elkeles’ tenure
States of pharmacy licensure
50 states
PetMed Express is licensed as an online pharmacy across all U.S. states
Key Terms
independent director, Compensation and Human Capital Committee, Corporate Governance and Nominating Committee, Non-Employee Director Compensation Program, +2 more
6 terms
independent director regulatory
"The Board has determined that Dr. Elkeles qualifies as an independent director"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
Compensation and Human Capital Committee financial
"appointed to serve immediately on the Board’s Compensation and Human Capital Committee"
A compensation and human capital committee is a board-level group that sets and oversees executive pay, employee incentive plans, hiring and retention strategies, succession planning, and workplace policies. Think of it as the company’s talent and pay steering team — it shapes who gets hired or promoted, how employees are rewarded, and how workforce risks are managed. Investors care because those choices drive labor costs, company performance, leadership stability and reputation, all of which affect long-term value.
Corporate Governance and Nominating Committee regulatory
"and Corporate Governance and Nominating Committee"
A corporate governance and nominating committee is a group of independent board members who set rules for how a company is run and choose or vet candidates for the board and senior leadership. Think of them as the company’s rulebook authors and hiring panel for its top oversight team; their choices and policies influence management accountability, risk oversight and investor confidence, so investors watch them for signs of strong leadership and transparency.
Non-Employee Director Compensation Program financial
"will receive compensation in accordance with the Company’s Non-Employee Director Compensation Program"
Regulation FD Disclosure regulatory
"Item 7.01 Regulation FD Disclosure."
Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.
forward-looking statements regulatory
"This press release may contain “forward-looking statements”"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did PETS announce on September 15, 2026?
PetMed Express appointed Tamar Elkeles, Ph.D. as a director effective September 17, 2026 and increased the size of its Board of Directors to 5 members. She will serve until the Company’s 2027 annual meeting or until a successor is elected and qualified.
Is Tamar Elkeles considered an independent director at PETS?
Yes. The Board determined that Tamar Elkeles qualifies as an independent director under Nasdaq Stock Market listing standards and the Company’s Corporate Governance Guidelines. She joins as a non-employee director and will be compensated under the Company’s Non-Employee Director Compensation Program.
What committees will Tamar Elkeles serve on at PetMed Express (PETS)?
Tamar Elkeles has been appointed to serve immediately on the Compensation and Human Capital Committee and the Corporate Governance and Nominating Committee. The press release states she will serve as Chair of the Compensation and Human Capital Committee.
How will Tamar Elkeles be compensated as a director of PETS?
PetMed Express states that Tamar Elkeles will receive director compensation in accordance with its Non-Employee Director Compensation Program, which is described in Exhibit 10.7 to the Company’s Form 10-K for the fiscal year ended March 31, 2026. She will also enter into a standard director indemnification agreement.
What experience does Tamar Elkeles bring to the PetMed Express (PETS) Board?
Tamar Elkeles, age 57, has over 30 years of experience as an executive, board member and strategic advisor in technology, enterprise software and human capital. She previously led human capital at XCOM Labs and Qualcomm and serves on several corporate boards and advisory boards.
Did PetMed Express issue a press release about the new director appointment?
Yes. On September 21, 2026, PetMed Express issued a press release describing the appointment of Tamar Elkeles as a new independent director and Chair of the Compensation and Human Capital Committee. The press release is included as Exhibit 99.1 to the report.
AI-generated analysis. How Rhea-AI works. Not financial advice.
